» Articles » PMID: 17823658

Elevation of RNA-binding Protein CUGBP1 is an Early Event in an Inducible Heart-specific Mouse Model of Myotonic Dystrophy

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2007 Sep 8
PMID 17823658
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Myotonic dystrophy type 1 (DM1) is caused by a CTG trinucleotide expansion in the 3' untranslated region (3' UTR) of DM protein kinase (DMPK). The key feature of DM1 pathogenesis is nuclear accumulation of RNA, which causes aberrant alternative splicing of specific pre-mRNAs by altering the functions of CUG-binding proteins (CUGBPs). Cardiac involvement occurs in more than 80% of individuals with DM1 and is responsible for up to 30% of disease-related deaths. We have generated an inducible and heart-specific DM1 mouse model expressing expanded CUG RNA in the context of DMPK 3' UTR that recapitulated pathological and molecular features of DM1 including dilated cardiomyopathy, arrhythmias, systolic and diastolic dysfunction, and mis-regulated alternative splicing. Combined in situ hybridization and immunofluorescent staining for CUGBP1 and CUGBP2, the 2 CUGBP1 and ETR-3 like factor (CELF) proteins expressed in heart, demonstrated elevated protein levels specifically in nuclei containing foci of CUG repeat RNA. A time-course study demonstrated that colocalization of MBNL1 with RNA foci and increased CUGBP1 occurred within hours of induced expression of CUG repeat RNA and coincided with reversion to embryonic splicing patterns. These results indicate that CUGBP1 upregulation is an early and primary response to expression of CUG repeat RNA.

Citing Articles

FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models.

Weeden T, Picariello T, Quinn B, Spring S, Shen P, Qiu Q Commun Med (Lond). 2025; 5(1):22.

PMID: 39827287 PMC: 11742727. DOI: 10.1038/s43856-025-00733-w.


Alternative splicing dysregulation across tissue and therapeutic approaches in a mouse model of myotonic dystrophy type 1.

Hicks S, Frias J, Mishra S, Scotti M, Muscato D, Valero M Mol Ther Nucleic Acids. 2024; 35(4):102338.

PMID: 39391766 PMC: 11465180. DOI: 10.1016/j.omtn.2024.102338.


Identification of an RNA-binding perturbing characteristic for thiopurine drugs and their derivatives to disrupt CELF1-RNA interaction.

Tan Y, Zhao Z, Han Q, Xu P, Shen X, Jiang Y Nucleic Acids Res. 2024; 52(18):10810-10822.

PMID: 39268573 PMC: 11472155. DOI: 10.1093/nar/gkae788.


Curriculum vitae of CUG binding protein 1 (CELF1) in homeostasis and diseases: a systematic review.

Qin W, Shi J, Chen R, Li C, Liu Y, Lu J Cell Mol Biol Lett. 2024; 29(1):32.

PMID: 38443798 PMC: 10916161. DOI: 10.1186/s11658-024-00556-y.


Cardiac involvement in patient-specific induced pluripotent stem cells of myotonic dystrophy type 1: unveiling the impact of voltage-gated sodium channels.

Pierre M, Djemai M, Chapotte-Baldacci C, Pouliot V, Puymirat J, Boutjdir M Front Physiol. 2023; 14:1258318.

PMID: 37791351 PMC: 10544896. DOI: 10.3389/fphys.2023.1258318.


References
1.
Tokgozoglu L, Ashizawa T, Pacifico A, Armstrong R, Epstein H, Zoghbi W . Cardiac involvement in a large kindred with myotonic dystrophy. Quantitative assessment and relation to size of CTG repeat expansion. JAMA. 1995; 274(10):813-9. View

2.
Ludatscher R, Kerner H, Amikam S, Gellei B . Myotonia dystrophica with heart involvement: an electron microscopic study of skeletal, cardiac, and smooth muscle. J Clin Pathol. 1978; 31(11):1057-64. PMC: 1145484. DOI: 10.1136/jcp.31.11.1057. View

3.
Mankodi A, Lin X, Blaxall B, Swanson M, Thornton C . Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res. 2005; 97(11):1152-5. DOI: 10.1161/01.RES.0000193598.89753.e3. View

4.
Timchenko N, Patel R, Iakova P, Cai Z, Quan L, Timchenko L . Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. J Biol Chem. 2004; 279(13):13129-39. DOI: 10.1074/jbc.M312923200. View

5.
Amack J, Reagan S, Mahadevan M . Mutant DMPK 3'-UTR transcripts disrupt C2C12 myogenic differentiation by compromising MyoD. J Cell Biol. 2002; 159(3):419-29. PMC: 2173077. DOI: 10.1083/jcb.200206020. View